Core Viewpoint - Green Kang Biochemical has completed the transfer of its controlling shareholder from Shanghai Kangyi to Zongteng Network, alongside the divestiture of its photovoltaic assets, amidst ongoing financial struggles and operational challenges in its core veterinary medicine business [1][3]. Group 1: Company Background and Financial Struggles - Green Kang Biochemical, originally focused on veterinary drug R&D and production, has faced declining net profits since its IPO in 2017, culminating in significant losses starting in 2021 [1][2]. - The company reported a total loss of 789 million yuan from 2022 to 2024, with its net assets reaching -24.54 million yuan by the end of 2024, leading to a risk of delisting [3][4]. Group 2: Transition to Photovoltaic Business - The company attempted to pivot to the photovoltaic sector by acquiring Jiangxi Weike New Materials Technology Co., with a premium of 632%, but this transition resulted in substantial losses due to falling prices in the photovoltaic industry [2][3]. - The photovoltaic business accounted for approximately 36% of the company's revenue in 2024, but the overall revenue from the veterinary business remains critical, constituting 84% of the adjusted revenue [5][6]. Group 3: New Controlling Shareholder and Future Prospects - Zongteng Network, the new controlling shareholder, specializes in cross-border logistics and reported a revenue of 27.105 billion yuan and a net profit of 1.122 billion yuan in 2024, raising questions about its ability to turn around Green Kang Biochemical's fortunes [6]. - The veterinary business has shown volatility, with a gross margin of only 7.35% in 2024, although it improved to 21.61% in the first half of the year due to rising pig prices [5][6].

Core Viewpoint - *ST绿康 has completed the transfer of control and the sale of its loss-making photovoltaic film business, which is expected to improve its future financial situation [1][2]. Group 1: Company Overview - *ST绿康, originally focused on veterinary pharmaceuticals and related products, attempted to diversify into the photovoltaic film sector through acquisitions in 2022, but this transition was unsuccessful [1]. - The company reported significant losses, with net profits of -122 million yuan in 2022, -222 million yuan in 2023, and projected -445 million yuan in 2024 [1]. Group 2: Control Transfer and Asset Sale - The original controlling shareholder, Shanghai Kangyi Investment Co., initiated the control transfer process in April 2023, culminating in the transfer to Fujian Zongteng Network Co. on November 25, 2023 [2]. - The asset sale involved the divestment of three subsidiaries related to the photovoltaic business at a price of 0 yuan, effectively removing the loss-making assets from the company's balance sheet [2]. Group 3: New Controlling Shareholder - The new controlling shareholder, Zongteng Network, established in 2009, specializes in global cross-border e-commerce infrastructure services, focusing on warehousing and logistics [3]. - For the fiscal year 2024, Zongteng Network reported total revenue of 27.105 billion yuan and a net profit of 1.122 billion yuan, with total assets of 10.443 billion yuan and total liabilities of 4.8 billion yuan [3].

Group 1 - The core point of the article is the completion of the share transfer of *ST Lvkang, changing its controlling shareholder from Shanghai Kangyi Investment Co., Ltd. to Fujian Zongteng Network Co., Ltd., with the actual controller changing from Lai Tanping to Wang Zuan [2] - *ST Lvkang received notification from the share transfer parties that the securities transfer registration procedures related to the share transfer to Zongteng Network were completed on November 21, with Zongteng Network holding 46.6084 million shares, accounting for 29.99% of the company's total share capital [2] - *ST Lvkang focuses on the research, production, and sales of veterinary drugs and has established a dual business model of "animal health products + photovoltaic film products" following the acquisition of Lvkang Yushan and the establishment of Lvkang Haining [2] Group 2 - Zongteng Network positions itself as a global cross-border e-commerce infrastructure service provider, focusing on cross-border warehousing and logistics, offering integrated logistics solutions for global cross-border e-commerce merchants, export trading companies, and overseas brands [2] - This acquisition marks Wang Zuan's first listed platform [3]

Core Viewpoint - *ST Lvkang is facing significant uncertainty regarding its ability to continue operations due to insolvency, while simultaneously engaging in a series of capital actions such as equity transfers that appear to be self-rescue efforts. The question arises whether the company will pursue a backdoor listing or engage in "tri-party transactions" in its capital operations, with the former being potentially more uncertain given the urgency of maintaining its listing status [1] Group 1: Financial Performance and Business Transition - Lvkang Biotech, originally focused on veterinary drug raw materials and probiotics, has seen a decline in performance since its listing in 2017, with a net profit drop of 6.97%, 13.08%, 23.73%, and 24.15% from 2017 to 2020 [2] - In 2021, the company reported a revenue of 363 million yuan, a year-on-year increase of 17.93%, but incurred a net loss of 26.04 million yuan, a decline of 160.28% compared to the previous year [2] - The company entered the photovoltaic film sector in 2022 through acquisitions, leading to a significant stock price increase from around 10 yuan to a peak of 65.9 yuan, representing a more than fivefold increase [2] Group 2: Ongoing Losses and Financial Challenges - Lvkang Biotech has continued to incur losses, with net profits of -122 million yuan, -222 million yuan, and -445 million yuan projected for 2022, 2023, and 2024 respectively, indicating a worsening financial situation [3] - The photovoltaic film business has negatively impacted the company's financial statements due to low gross margins and high financial costs associated with increased bank loans and financing leases [3] - As of December 31, 2024, the company's current liabilities exceeded current assets by over 1 billion yuan, raising significant doubts about its ability to continue as a going concern [4] Group 3: Shareholder Changes and Market Reactions - On April 24, 2025, Lvkang Biotech announced a change in control, with major shareholders transferring shares to Zongteng Network at a price of 13.73 yuan per share, totaling approximately 639.93 million yuan [5] - This transfer will increase Zongteng Network's ownership to 29.99%, surpassing the previous controlling shareholder's stake [5] - The market is speculating whether Zongteng Network's involvement indicates a backdoor listing or a different capital strategy, especially as the company also announced plans to divest its photovoltaic assets [9] Group 4: Strategic Moves and Future Outlook - Lvkang Biotech's recent capital operations, including the divestiture of its photovoltaic film business, may be aimed at clearing obstacles for future transactions [9] - The company signed an asset transfer agreement on April 24, 2025, to sell all assets and liabilities related to its photovoltaic film business to a joint venture established by its shareholders [9] - The potential for a backdoor listing or tri-party transaction remains uncertain, with regulatory hurdles and the urgency of maintaining its listing status complicating the situation [9]